Drug intelligence / Profile preview

IIT-ATLG-68

Development stage: Unknown
Lead developer: Neovii Pharmaceuticals
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

IIT-ATLG-68 is a polyclonal rabbit anti-human T-lymphocyte globulin (ATLG) therapeutic candidate being developed by Neovii Pharmaceuticals. Currently in Phase 2 clinical development, it is primarily investigated for use in stem cell transplantation (SCT) conditioning, specifically for patients with Multiple Sclerosis (MS) undergoing hematopoietic stem cell transplantation. The drug functions as an immunosuppressive agent by depleting T-lymphocytes and modulating immune responses through mechanisms such as complement-dependent cytotoxicity and apoptosis. By targeting a broad range of T-cell surface antigens, IIT-ATLG-68 aims to facilitate successful engraftment and prevent graft-versus-host disease (GvHD) or autoimmune relapse in the context of cellular therapies.

Other names: MSIIT-ATLG-68 MSIIT-ATLG68 MSIIT-ATLG 68 MSanti-t-lymphocyte globulin (rabbit)

Targets

CD28 (Cluster of Differentiation 28)CD7 (CD7 antigen)PTPRC (Receptor-type tyrosine-protein phosphatase C)CD2 (T-cell Surface Antigen CD2)CD4 (T lymphocyte surface antigen)CD8A (T-cell surface glycoprotein CD8 alpha chain)CD5 (T-cell surface glycoprotein CD5)IL2RA (Interleukin-2 receptor alpha subunit)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on IIT-ATLG-68.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IIT-ATLG-68.

Explore the full profile